FRM
ZNTL icon

Fox Run Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Fox Run Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,067
Closed -$164K – 1156
2024
Q2 		$164K Buy
+40,067
New +$447K 0.03% 696
2023
Q3 		– Sell
-7,760
Closed -$219K – 1037
2023
Q2 		$219K Buy
+7,760
New +$186K 0.06% 556

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fox Run Management's ZNTL Position: Q3 2024 in Review

Fox Run Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 40,067 shares — an estimated $164K sold.

Fox Run Management first reported a position in ZNTL in Q2 2023 and held it in 2 quarters. The position peaked at $219K in Q2 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Fox Run Management reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Fox Run Management sold 40,067 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $164K.
  • Fox Run Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Fox Run Management's Zentalis Pharmaceuticals position peaked at $219K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Fox Run Management's 13F filing for Q3 2024, filed 12 Nov 2024.